initi coverag global pharmaceut innov deliv sustain
messag initi coverag global pharmaceut stock resum coverag posit
sector see headwind abat innov new product drive mid- upper-single-digit sale
ep growth compound-annual-growth-rate coverag includ /ireland domicil pharmaceut compani european
compani best idea base expect continu rapid expans immuno-oncolog i/o market
drive consensu contribut keytruda also benefit use partner oncolog asset lynparza
lenvima expand global near-term growth bolster gardasil merck anim health busi underappreci
pipelin ph asset provid upsid long-term growth prospect stock-select scoreboard also highlight
azn-lon among favorit buy-rat stock follow novo stock rate neutral gsk-lon novn-
san-par
nearli decad deal restructur rebuild global pharma invest deliv growth
believ sever stock room run believ time investor take fresh look global pharmaceut stock
headwind abat group enter strongest new product cycl sinc late posit sever key reason
includ new gener competit brought loss exclus loe reach lowest point
volum mix overtaken price increas main driver growth emerg market growth particularli china
sustain innov much improv pipelin matur quickli regulatori approv near all-tim high
partner tuck-in deal highlight benefit risk-shar
pharma better posit weather potenti price pressur follow direct evolut toward oncolog rare
diseas immunolog neurosci challeng face new drug launch primari care larg specialti like
endocrinolog cardiolog highlight critic import price power reimburs date differenti new drug class
area high unmet need like oncology/immuno-oncolog rare disease/gen therapy/gen edit neurosci seen
limit pushback payer particularli breakthrough innov like immuno-oncolog basi year nobel prize
medicin market expect doubl addit new
biopharmaceut agent develop recent approv potenti chang treatment sever resist depress
agn rapastinel chronic debilit pain lly/pf tanezumab sever hemophilia roch hemlibra advanc
immunolog turn inflammatori arthritis/ psoriasi nvss cosentyx lli taltz atop dermat regn/sni dupix
sever resist asthma gsk nucala azn fasenra regn/sni dupix manag diseas new anemia treatment
azn/fgen roxadustat could disrupt expand esa market base estim new treatment
class sale potenti
high valu pipelin catalyst expect next month shortag opportun investor
captur alpha view number competit catalyst increas pure market-expand catalyst grow less
frequent expect market differenti quickli among winner loser
page analyst certif import disclosur
initi coverag global
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
period innovation-driven growth
estim new gener competit brought loss exclus loe
reach lowest point although biosimilar penetr grow threat
larg concentr roch
volum mix overtaken price hike main driver growth pharma
compani forc less reliant price hike earn growth drive busi mix
toward high unmet need therapeut area ta better price power sell effici
 government intervent risk look balanc across manufactur suppli chain
chang rebat structur increas avail penetr biosimilar like
inevit free market price threat current administr view
emerg market growth sustain particular china rapid growth remain strong
support innovation-friendli polici allow global multin advanc new therapi
gain reimburs faster
innov much improv pipelin matur matur quickli sever
compani pois see acceler growth driven product
expect global pharma continu invest manag team highlight improv
product sever key growth market includ oncolog immuno-oncolog orphan
diseas blood disord psychiatry/neurolog pain autoimmun disord
partnering/tuck-in win big deal share high-risk/high-return opportun
optim across domain expertis oper excel acceler develop
page analyst certif import disclosur
price
note san novn report total sale consensu comparison made total product sale subsequ slide
note revenu million
page analyst certif import disclosur
priceytd guggenheim estimatescompanytickerratinga price p/eallergan myer lilli co agnovn-swxneutralchf chf chf chf nordisknovo b-csebuydkk group price-to-earnings ptupsid ptprice target pt price-to-earnings multipl pt guggenheim vs consensu sale ep
price
note san novn report total sale total revenu consensu comparison made total product sale
note revenu million
page analyst certif import disclosur
revenu revenu ep ep delay introduct advair gener benefit headwind currenc headwind togeth loss ciali profit modestli consensus- upsid keytruda main driver sale ep consensu consensu sale despit fx tailwind forecast exclud sale gener asset estimate transact close year-end aurobindo fx headwind sale consensu sale insulin sale expect currenc expect tailwind ep despit detail guidanc consensu appear factor sale med derm asset almiral fulli account profit restasi gener launch- azn includ item core/adjust ep consensu includ contribut well us assum continu declin y/i fundament thesis- expect spend increas support new ph i/o program partial off-set sg reduct mix also put downward pressur gross margin varianc consensusgsr commentsconsensu estimatesguggenheim p/eallergan myer lilli co ovn-swxneutralchf chf chf chf chf chf chf nordisknovo b-csebuydkk dkk dkk dkk initi coverag global pharmaceut stock
rate stock buy stock neutral
top pick azn support stock select framework includ
upsid vs consensu sale ep forecast
posit risk/reward needle-mov pipelin catalyst
shift busi mix high valu therapeut area drive oper margin expans
addit stock rate buy novo
stock rate neutral gsk novn san
stock acceler cagr substanti faster
faster driven new product launch late stage pipelin asset typic see
initi period multipl expans ahead sale earn growth acceler
sale ep upsid vs expect either sell-sid consensu buy-sid
expect driven faster-than-expect penetr new product new market
area curv profit acceler better expect new
product launch area high unmet need reimburs risk low
page analyst certif import disclosur
attract valuat posit risk/reward head rapastinel abicipar bima
sr catalyst believ agn nmda modul could game changer
new product launch oncolog sever asthma drive fastest sale ep
growth global pharma roxadustat ph readout could transform treatment
anemia imfinzi treme studi pois deliv result arent stock
impress execut industri lead fast-follow downsid limit despit major
cv outcom studi expect ye potenti revalu around tanezumab ph
pois deliv sale ep upsid vs consensu oper leverag keytruda
growth expand global partner product lynparza lenvima
underappreci pipelin particularli long-term hiv
exposur diabet price pressur still declin long
categori price disciplin remain see qualiti growth
near-term opdivo catalyst larg stock risk-reward balanc ahead
sever competitor catalyst pois read
durabl hiv busi vaccines/biolog busi oncolog immunolog pipelin
could emerg still bit earli upsid consum stori pharma
shift pure-play human health posit alcon spin like gener valu
addit pipelin catalyst need drive oper leverag
earn risk near-term strong dividend reason valuat competit
intens build vs dupix hemophilia franchis
page analyst certif import disclosur
stock select framework base criteria
much stock
dcf valuat upsid gsr base case
posit ev/ebit regress
sequenti improv year compound-annual-growth-rate vs
improv gsr reimburs leverag
page analyst certif import disclosur
coverag summari top pick base rate framework
addit stock rate buy
page analyst certif import disclosur
valuat fair valu price target deriv via discount cash flow analysi dcf
product-level growth forecast
consist post-loss exclus assumpt prior generic/biosimilar entri re-evalu
gener enter market
detail market model major competit categori oncology/immuno-oncolog diabet
hiv cgrp migrain risk-adjust est key pipelin asset tanezumab pain
consist wacc use discount rate global pharma meaning differ
access capit compani market cap billion sale profit
wacc global pharma
nopat base assess cost open scienc
 assumpt reflect management long-term guidanc well busi mix
cog calcul base mix high corpor low margin products/busi
 base larg management guidanc need pipelin particularli ph develop
sg reflect management guidanc opti effici sell base mix new market entri
tax rate base larg full year adjust tax rate exclud item
page analyst certif import disclosur
view support
keytruda domin posit nsclc continu
label expans multipl addit solid tumor well
intenational market penetr drive oper margin leverag
partner product lenvima lynparza deliv
big keytruda get io competit
azn eisai oncolog partnership expand role
io-chemo combo new tumor type indic
lynparza singl agent io-combo expand role
parp mechan beyond brca mutat tumor type
combin peak end-us sale
valu mrk pipelin contribut medium
despit limit number late-stag pipelin opportun
success grow thru loss januvia
much growth left gardasil pcv
increas emphasi mrk earli stage develop
opportun success advanc ph
studi part daili treatment regimen enter
mid-stag studi long-act depot formul
supplant hold pcv
keytruda phase top-lin result tnbc
keytruda phase top-lin result neoadjuvant/adjuv
keytruda phase top-lin result sclc
note close
page analyst certif import disclosur
global pharmaceut compani product core categori includ diabet cancer vaccin hospit acut care
human health well anim health busi
report sale consensu expect busi grow sale
within health sale mrk oncolog busi led keytruda compani flagship busi
consensu estim unit overal y/i growth keytruda
next month expect import clinic updat keytruda pneumococc vaccin hiv candid
page analyst certif import disclosur
dcf-base price target forecast
sale profit global pharma discount
rate assum termin growth rate
deceler gardasil growth
neg keytruda readout next month
chang price environ oncolog drug
sale compani three
largest product keytruda januvia gardasil
contribut combin forecast
sale driven larg consensu
forecast vs keytruda
combin sale gardasil januvia
pos-adjust pipelin contribut
sale
ebit margin bp higher
step
lynparza succe platinum-sensit cancer
keytruda succe neoadjuvant/adjuv tnbc
keytruda combin becom market leader rcc
succe hiv/aid
keytruda miss sale new dataset tnbc
gastric rcc fall short expect
fail replic viral suppress phase
pneumococc vaccin inferior
head head phase data
page analyst certif import disclosur
posit view azn reflect
high-single-digit sale double-digit ep growth
continu leadership respiratori diseas pipelin
product fasenra tezepelumab
success proof cv overal safeti near-term high
risk/high reward opportun roxadustat anemia
imfinzi broaden base grow revenu beyond
high risk/high reward roxadustat deliv epo-lik
efficaci placebo-lik safeti
cancer lynparza maintain best class parp
partial off-set continu relianc extern
azn show increment benefit combin
revenu support cash flow oper margin
view azn low oper margin pois substanti
improv new product portfolio continu
imfinzi inhibitor tremelimumab
roxadustat phase top-lin result anemia
imfinzi phase top-lin result nsclc
lynparza phase top-lin result pancreat cancer
calquenc phase top-lin result cll patient
note close
page analyst certif import disclosur
astrazeneca london-bas biopharmaceut compani oper broad rang therapeut categori includ
oncolog respiratori cardiovascular neurosci
consensu forecast azn deliv sale oper margin adjust basi
azn compani transit near tail-end signific loe period primari care busi look return
growth flagship oncolog franchis imfinzi tagrisso mrk-partner oncolog collabor includ lynparza
next month azn number catalyst includ key data readout product anemia bladder pancreat
 cancer well leukemia
page analyst certif import disclosur
dcf valuat azn base
wacc line compani coverag
univers termin growth
worsen access price diabet respiratori
surpris safeti develop roxadustat calquenc
prove inferior efficaci imbruvica
combin sale growth product imfinzi tagrisso
lynparza fasenra increas rapidli
farxiga sale grow
driven strong intenational categori growth
pos-adjust pipelin
lynparza succe pancreat cancer and/or ovarian
imfinzi succe beyond stage lung cancer either
imfinzi tremelimumab metastat cancer lung
roxadustat achiev best case result deliv efficaci
line epo placebo-lik safeti
tezepelumab anti-tslp succe strong safeti
profil sever eosinophil asthma ige-driven
pipelin failur lynparza roxadustat tezepelumab
new imfinzi dataset lung cancer fall short
page analyst certif import disclosur
posit view reflect
sustain leadership medic aesthet botox
juvederm coolsculpt
double-digit growth key line growth product vraylar
posit risk/reward high impact catalyst
long-term pipelin option relamorelin novel
agent diabet gastroparesi
attract valuat rel global pharma peer
abicipar pegol phase top-lin result wet-amd
bimatoprost sustained-releas phase studi glaucoma
rapastinel phase top-lin result major depress
abicipar pegol commerci viabl current
formul wet-amd new formul current
compar on-market agent
oral cgrp agent histori failur due liver
toxic final mitig risk
acut migrain market evolv if/when
agent market
rapastinel among group new rapid act agent
major depress disord ph read-out start
rapastinel despit challeng success
larger depress studi replic benefit gave
fda breakthrough design base two phase
page analyst certif import disclosur
note close
allergan global pharmaceut compani incorpor ireland market lead posit medic aesthet
neurosci women health ophthalmolog gastroenterolog
consensu forecast deliv sale oper margin adjust basi
domin medic aesthet w/ botox juvederm coolsculpt compani largest franchis sale
therapeut growth driver includ botox therapeut legaci forest product viibryd depress vraylar antipsychot
migrain
page analyst certif import disclosur
valu share base dcf analysi
wacc consist discount rate use
global pharma co termin growth vs global
pharma reflect cost agn open scienc strategi
botox use declin due cgrp mab
clinic failur atogep rapastinel relamorelin
forecast sale medic
aesthet led botox cosmet contribut
total revenu
forecast base busi reset sale
growth reacceler
pos-adjust pipelin repres
total sale
rapastinel oral nmda program succeed ph
rapastinel fail adjunct mdd studi
abicipar inflamm rate unchang new
page analyst certif import disclosur
top pick current trade discount peer ev/ebit
compar compani forecast consensu use ev/ebit regress
vs reflect materi differ qualiti consensu estim
consensu ev/ebit regress fall rel line azn look attract
rel ebit growth prospect
page analyst certif import disclosur
clinic catalyst roadmap coverag select -a
head neck cancer
head neck cancer
note low level medium level high level readout may delay base compani guidanc
page analyst certif import disclosur
clinic catalyst roadmap coverag select -b
head neck cancer
secondari prevent cv
page analyst certif import disclosur
clinic catalyst roadmap coverag select -c
page analyst certif import disclosur
clinic catalyst roadmap coverag select -a
head neck cancer
nsclc high tmb
note low level medium level high level readout may delay base compani guidanc
page analyst certif import disclosur
clinic catalyst roadmap coverag select -b
note low level medium level high level readout may delay base compani guidanc
page analyst certif import disclosur
clinic catalyst roadmap coverag select -c
hemophilia
hemophilia
note low level medium level high level readout may delay base compani guidanc
page analyst certif import disclosur
clinic catalyst roadmap coverag select -a
migrain
note low level medium level high level tent estim assum file nda
page analyst certif import disclosur
clinic catalyst roadmap coverag select -b
page analyst certif import disclosur
clinic catalyst roadmap coverag select -c
combo taf mek
hemophilia without
page analyst certif import disclosur
page analyst certif import disclosur
price
note san novn report total sale total revenu consensu comparison made total product sale
note revenu million
page analyst certif import disclosur
priceytd guggenheim estimatescompanytickerratinga price p/eallergan myer lilli co agnovn-swxneutralchf chf chf chf nordisknovo b-csebuydkk hold ltd rog-swxncchf chf chf chf group price-to-earnings ptconsensu estimatesupsid ptprice target pt price-to-earnings multipl pt global pharmaceut comp sheet contd consensu estim
note base consensu estim
note revenu million
page analyst certif import disclosur
companytickershar o/smarket cap mm enterpris valu mm dividend yieldev/epeg ratioev/e/gabbvieabbv squibbbmi johnsonjnj lillylli chf chf nordisknovo b-cse dkk chf ep sale compound-annual-growth-rate theme
pharma manag team anticip continu pressur global net price biopharmaceut
product drive shift away primari care toward either special cash-pay market
largest singl payer world trump administr effort negoti better price
reduc cost consum moder risk long pbm rebat scheme remain focu
temporari disrupt expect democrat sweep mid-term elect would surpris concern
price power reimburs access critic believ remain high within differenti
diseas condit rare diseas oncolog neurology/cn drive higher growth valuat
post-tax reform portfolio optim shareholder-friendli capit alloc reflect lli elanco
carv novn plan alcon spin expect targeted/bolt-on continu mega-cap deal
remain favor wake sustain product new product launch improv profit
broadli speak high valu pipelin catalyst see next month shift
growth/address market catalyst group win competitive/market share catalyst winners/los
see key market growth catalyst azn beneficiari
competit catalyst look well-posit bmi success key catalyst may alreadi
bake current consensu forecast san face headwind competitor catalyst
page analyst certif import disclosur
pharma price-to-earnings multipl expans close tie major new drug
launch pipelin innov anticip period ep growth
approv multipl
note
sinc pharma trade averag premium ps price-to-earnings multipl
multipl seen correl new drug launch breakthrough
pipelin innov ytd group multipl rel perform vs improv
price concern moder market shift under-perform defens group
page analyst certif import disclosur
improv period sale margin expans forecast
heel solid pipelin execut
tripl aventi
health consum
busi sold
spun
gener introduc
note
page analyst certif import disclosur
adjust oper marginspharma y/i sale growth larg cap pharma rebound group multi-year period
growth could final match
rel pharma price perform sale surpris histori vs
note
larg cap pharma exit period price sale under-perform sector deliv
new product launch pipelin catalyst money flow defens group
driven part valuat also concern economi abil extend
bull market beyond global trade disput slow wide anticip tighten easi
monetari polici could significantli hamper benefit global tax reform
page analyst certif import disclosur
price performancesal surpris histori vs sale surpris historypharma vs price perform pharma rel perform vs close tie
rel price power appear stabil
y/i pharma price perform vs pharma prep vs finish good ppi
normal
page analyst certif import disclosur
price perform rel chang ppi pharma vs finish consum good insur coverag stabl payer consolid formulari
manag tactic unlik worsen
us health insur statu expect remain
pbm market consolid compani
manag commerci cover live
though healthcar debat continu
increas consolid payer buy power
insur statu us expect remain
stabl live cover continu expand
uninsur expect declin albeit
modestli variou initi improv
competit lower out-of-pocket cost
consum within medicare/medicaid
explor washington pharma compani
remain keenli focus market
willing pay innov
follow number merger within manag
care along increas use close
formulari exclus formulari access
cite biggest driver increas
rebat drug compani hit matur
highli competit categori like respiratori
diabet particularli hard cite major
player categori novo
sanofi diabet gsk azn respiratori
page analyst certif import disclosur
new drug
pdufa date
drug approv
design
first-in-class fda
car-t gene tx vision
antisens oligonuc sma oncolyt viru
exclus indic expans already-approv drug
page analyst certif import disclosur
larg pharma trade pharma recent
note
histor trade signific premium larg pharma larg cap biotech pharma
trade near pariti larg pharma leadership excit new therapeut area like immuno-
oncolog autoimmun rare diseas togeth strong execut high growth emerg
market like china suggest price-to-earnings discrep may longer warrant may
particularli true larg biotech enter period slow growth intensifi competit
page analyst certif import disclosur
meanhighest quartilelowest rel p/epharma vs biotech rel pemeanhighest quartilelowest quartilemeanhighest quartilelowest rel p/epharma vs med-tech rel pemeanhighest quartilelowest guggenheim therapeut view price power reimburs
leverag put oncolog diseas cns/neuro top
note categori score scale lowest reimburs leverag highest reimburs leverag
page analyst certif import disclosur
reimburs leverag score categoryhcvi /vac hivcancer/ iodiabetescvrespiratoryimmuno/ rheumcns/ neurogirar diseaseopht unmet size invers within buyer guggenheim view azn lli transform
underway agn worth watch
calcul weighted-averag reimburs leverag
score compani coverag use sale
forecast ta forecast model
chang
cns/pain pipelin notabl
rapastinel oral cgrp agent
declin cv inhal respiratori
note includ pharma vaccin gener biosimilar product line
slow io franchis growth loss
sprycel
growth competit immunolog space
hiv/vaccin oncolog larger mix
declin cv good off-set oncolog
growth vaccin w/ gardasil pipelin
declin cv diabet mostli januvia
littl chang busi mix
increas immuno/rheum
cosentyx stabl ms pipelin
off-set declin oncolog
acquisit rare blood diseas
growth genzym orphan diseas
busi growth immuno-rheum
page analyst certif import disclosur
democrat major hous could stall effort overhaul
drug price look like republican take senat
trump drug propos build momentum still
bark bite
may trump deliv much-anticip speech drug
price reform despit concern would mean
pharma profit speech target pharma
compani specif lack specif reform sent
healthcar index time includ drg
hh identifi strateg initi improv drug
competit incent lower drug list price out-of-
pocket cost plan rang broad aspir
reduc drug price arbitrag exist us eu
drug cost specif initi give medicar
part drug program author negoti lower price
certain drug medicar part
mid-term result could headwind reform
republican current control senat howev
seat current grab mid-term elect
held senat caucu democrat
rest republican win senat democrat need
retain current seat flip republican seat long
shot sinc democrat seat state trump
hous seat elect current analys
fivethirtyeight com suggest chanc democrat
take control lower chamber republican per
support administr effort reduc patient pocket cost expens innov ken
way drug rebat work go chang posit real innov break rebat wall suppli
chain chang unknown pbm distributor dave rick chairman ceo
go marketplac dont rebat ian read chairman ceo
page analyst certif import disclosur
sever year declin growth iqvia expect price growth
remain consist
iqvia us price growth compar protect brand invoic price net price
exist product net price growth
annual spread list price growth vs net price growth expect stabl follow
period spread widen dramat due aggress tactic pharmaci benefit
manag increas competit limit access pharma manag team applaud
prospect lower pocket cost normal competit landscap unintend
risk suppli chain poorli understood
iqvia nation sale perspect iqvia institut understand driver drug expenditur us- sep
page analyst certif import disclosur
expect emerg market china becom import
addit sourc growth
expans public healthcar china
number new case
nation spend pharmaceut
align global standard
popul price
lack capac backlog
barrier foreign-
increas access clinic trial
foreign-develop new drug
requir prior nda/maa
reform clinic trial manag
page analyst certif import disclosur
highlight growth driver global pharma
page analyst certif import disclosur
themat coverag consist well-diversifi pharmaceut
compani broad reach number major therapeut categori
page analyst certif import disclosur
biosimilar dream somea nightmar
page analyst certif import disclosur
biosimilar access barrier come chang
current market sinc ema approv biosimilar
differ refer brand contrast fda greenlight first
biosimilar zerxio aug biosimilar
approv launch collect
lli basaglar although file new drug wide view
biosimilar lantu seen swift uptak
competit landscap success biosimilar europ reflect
easier regulatori path impact government payer tactic like class-
base price tender post approv access barrier
includ litig block unfavor rebat scheme limit
impact biosimilar advoc increas biosimilar penetr
trump administr via fda could spark faster eros
brand biolog within biopharma roch risk biosimilar
eros revenu face biosimilar threat
watch implement new polici assign individu
reimburs code biosimilar fda biosimilar action fda
annual sale product expos
consensu forecast world-wide biosimilar market grow
us biosimilar market account
less global sale time
view reflect sale brand biolog
expos threat biosimilar global howev
everi brand biolog face eros risk complex
molecul high manufacturing/compli demand
botox less risk biosimilar competit
swing factor expand use access biosimilar
goal trump administr like reduc pocket
cost consum overal hc budget beyond fda effort
expand biosimilar approv reduc legal patent
suppli chain rebat barrier may requir legisl action
biosimilar threat top sale drug
approv usa
approv eu
guggenheim secur llc ema evaluatepharma fda compani report note evaluatepharma forecast biosimilar entri time could compani includ rhhbi shpg
page analyst certif import disclosur
diabet count leader deliv cv
page analyst certif import disclosur
diabet market class differenti
current market diabet market highli competit
fragment accord evaluatepharma insulin
market repres overal diabet sale
expect grow low- mid-single-digit
insulin share overal market declin oral
inhibitor agonist grow consensu expect overal
demand diabet product remain high estim
year growth compound-annual-growth-rate price pressur insulin
market expect abat place
burden growth market
watch lli rewind studi cv outcom studi
trulic novo oral semaglutid cv safeti studi
pdufa phase
consensu overal market growth
mid-singl digit come primarili
compound-annual-growth-rate
compound-annual-growth-rate insulin grow low singl digit declin
driven gener januvia
consensu overal market
assumpt similar street
view driver upsid diabet estim
limit given categori competit howev
downsid risk payer get
aggress access price categori
view evolut diabet market
page analyst certif import disclosur
categori growth declar success acceler may
key heart failur studi due
current market first approv jnj invokana
plagu seri unexpect safeti concern
rapidli lost share lly/boehring ingelheim
jardianc azn farxiga jardianc lead categori
surpris impress benefit seen empa-
studi cv-death label claim kidney benefit
exploratori endpoint growth slow recent
farxiga success one co-primari endpoint
declar valid cv benefit class fail
show benefit cv death jardianc consensu
forecast grow
agent categori go gener
partner steglatro sanofi/lexicon zynquista
inhibitor review type
consensu overal categori expect
grow base
impli littl competit threat categori
competit concern new emerg necrot
fasciiti warn fda
deceler growth volum growth mid-singl digit
vs y/i growth howev intern growth
class strong lly- jardianc
farxiga see categori grow
compound-annual-growth-rate roughli line consensu
swing factor estim assum stabl price
categori dont assum oral semaglutid novo oral
direct competitor effect renal ckd
heart failur studi addit growth opportun
cv benefit continu tailwind growth
watch final declar studi result cv
outcom studi azn farxiga american heart
hf cv outcom heart failur lly/bi emperor-
azn dapa-ckd renal cv outcom chronic kidney
page analyst certif import disclosur
cv top-lin result sig reduct hospit heart failur cv death fewer mase event stat sig full data ahacv outcom hazard ratiospatientstrialcompanyclassbrand name battl player categori expans key rewind data
current market consensu estim categori
grow global displac
second largest class consensu expect insulin analog
grow mid-singl digit despit continu price pressur
expect categori grow low-doubl
digit mid-teen
competit landscap view segment
two player market novo account
global sale recent novo victoza once-daili
agonist market leader categori novo
resourc newli launch once-weekli product ozemp
better compet trulic lli once-weekli agonist
watch lli rewind studi cv outcom studi
trulic import data point continu growth
class
consensu forecast sale
categori grow consensu
assum trulic becom categori leader
impli success demonstr cv
benefit rewind modest rate convers
victoza ozemp sale two product
respect
view reflect estim categori
grow ahead
consensu driven continu categori expans
ozemp oral semaglutid
swing factor lli rewind cv outcom
novo oral semaglutid cv studi major near term
swing factor well emerg data
dual agonist mechan follow posit proof
concept data
victoza
chang
class
page analyst certif import disclosur
innov cure
page analyst certif import disclosur
hemophilia market like disrupt hemlibra hemophilia
hemophilia inhibitor market prior hemlibra
hemophilia inhibitor market small market
introduct provid reli immun toler induct
therapi fviii short half-lif shl agent
treatment bypass agent sinc hemlibra approv
uptak swift inhibitor patient
convert due good efficaci dose conveni
half-lif ehl agent offer better dose fviii shl
still need inject time per week oct
fda approv hemlibra label expans non-
inhibitor patient given hemlibra good efficaci once-
monthli dose believ meaning step-
chang ehl prophylaxi assum
once-monthli hemlibra limit market fitusiran data
gene therapi commerci impact emerg
impact hemlibra doesnt work type current
bypass agent san fitusiran once-monthli rnai
antithrombin could prefer nich market
alprolix novo refixia swift uptak
domin market take share shl
agent view long-term opportun cur gene
therapi uniqur
attract patient vs weekli dose fitusiran monthli
dose said commerci impact like mute
given limit long-term data gene therapi
page analyst certif import disclosur
roch hemlibra well-posit drive hemophilia market expans
fitusiran impact remain seen
hemophilia-a market expect global market reach
mainli driven prophylaxi roch hemlibra
offer competit price attract sc inject rout
forecast compound-annual-growth-rate sale total
sale hemlibra assum impli
competit landscap hemlibra alreadi see rapid uptak
among hemophilia patient inhibitor also like
leader non-inhibitor market believ sale could
reflect drug superior efficaci given recent
approv once-monthli dose believ futur san
fitusiran rnai biomarin gene therapi remain
uncertain given limit safeti data durabl
watch fitusiran phase atlas-a/b trial non-
inhibitor patient expect could redefin competit
landscap depend safeti efficaci readout
trial also expect
similar view overal market
howev think hemlibra demonstr much faster growth
given superior efficacy/dos recent label expans
non-inhibitor popul believ once-monthli hemlibra
set high bar rnai gene therapi although time
gene therapi potenti disrupt treatment paradigm
swing factor although current gene therapi suitabl
less quarter total patient due age exist
immun could bring potenti cure hemophilia patient
disrupt market long-term trial prove safe
gsr vs consensu hemophilia global sale
page analyst certif import disclosur
ehl rfix agent expect domin hemophilia market safeti
readout determin qure futur
hemophilia-b market anticip global market
reach mainli driven uptak rfix ehl
agent includ san alprolix novo rebinyn
competit landscap believ ehl rfix agent
replac rfix shl agent becom leader non-
inhibitor market captur tradit
bypass agent still domin small market
patient inhibitor without competit hemlibra
shown hemophilia market fitusiran could gain
share hemophilia patient especi
inhibitor howev initi growth rnai fitusiran
gene therapi would still slow due lack drug
safeti result
watch readout fitusiran phase
atlas-a/b trial expect efficaci data readout
hope-b trial phase trial
expect respect
indic almost increas total global sale
seem assum sale reduct shl rfix agent
fast uptak gene therapi upon launch
adopt ehl rfix agent replac prescript
shl rfix agent result signific sale declin shl rfix
agent gene therapi penetr like slow
due limit safeti data high payer barrier
fitusiran could achiev faster growth demonstr convinc
safeti data gene therapi potenti domin market
safeti readout around posit secur
support payer appropri price strategi
page analyst certif import disclosur
hiv
page analyst certif import disclosur
hiv growth key gild biktarvi gsk two-drug franchis consensu
current market estim size hiv market
gsk own
competit landscap us believ biktarvi
like becom go-to option us outsid us
market much cost-sensit taf-bas
regimen repres intern sale
highlight comfort less expens tenofovir disoproxil
critic viiv long-term success
consensu evaluatepharma consensu view
impli best case scenario gsk
gild hiv busi may fulli reflect
impact biktarvi legaci two three drug
combo us impact gener truvada
atripla eu consensu estim genvoya
triumeq vs two product
view reflect forecast hiv categori grow
compound-annual-growth-rate global growth biktarvi
gsk two drug franchis partial off-set declin
legaci franchis switch biktarvi us
gener eu/row
watch cabotegravir/rilpivirin hiv-nav
growth opportun longer-act agent
develop gsk could improv
complianc reduc risk develop resist mk-
long-act nrtti novel deliveri technolog
may open path annual everi regimen
page analyst certif import disclosur
page analyst certif import disclosur
cgrp antibodi expand migrain prophylaxi market
botox consensu number may need come
current market migrain patient seek
prophylaxi treatment us market estim
base frequenc topiram off-
label treatment migrain prevent
competit landscap approv botox sale
prevent chronic migrain estim
accord new antibodi treatment target
cgrp ligand receptor novn/amgn market
aimovig teva market ajovi market
emgal launch aggress market sampl
gear compel earlier better insur reimburs
condit primarili affect women age
compar well
launch
reimburs
impact payer
well understood
also assum mid-to-high singl digit
growth botox therapeut
view estim patient cgrp
antibodi therapi repres
chronic migrain suffer botox
patient therapi us forecast rel flat
sale take conserv approach
given dose conveni offer cgrp mab
earli aggress commerci strategi
rapidli evolv competit landscap anti-
swing factor expect formulari access
competitor behavior biggest swing factor
cgrp class drug
note cgrp estim base gsr prophi migrain model
page analyst certif import disclosur
migrain sale botoxcgrpatogepantproductiqvia trxiqvia sale iqvia sales/scriptlaunch full month acut migrain evolut depend payer primari
current market patient diagnos
migrain us alon acut migrain market highli
generic triptan account prescrib
treatment howev either dont respond becom
refractori triptan patient cardiovascular risk
competit landscap current market crowd
triptan domin player small percentag
patient treat dihydroergotamin nsaid
also carri cv warn less efficaci
three novel late-stag mechan current develop
focus treat patient either cv triptan-
term safeti top-line
consensu forecast new class acut migrain
treatment reach rimegep
gain share global sale
although migrain specialist check confirm
unmet need acut migrain market given wide
avail cheap gener
convinc payer valu new medicin
repres thu take conserv
approach market sale next-gen
agent consensu
growth opportun benefit
commerci footprint primari care well
sell synergi botox emgal
given similar
clinic profil
next-
therapi time
entri launch
execut like
play major role
page analyst certif import disclosur
migrain sale lasmiditanubrogepantdrugzolmitriptanlasmiditan ubrogep rimegep agonistor cgrp antagonistor cgrp antagonistnext milestoneon-market gener nda file safeti nda file file istudi freedom mg vs pbo mg vs pbo mg- vs pbo mg- vs pbo subject mb free mg vs pbo mg- vs pbo mg- vs pbo notabl ae srisk cv event chest pain dizzi nauseadizzi nausea fatiguenausea dri mouth case elev liver enzym deem unrel ubrogepantnausea multipl sclerosi new entrant help sustain
page analyst certif import disclosur
crowd ms market like littl overal growth near term
roch ocrevu biib tecfidera top market leader
ms market dozen disease-
modifi therapi ms make crowd space
particularli relaps form ms anticip
matur market ms remain overal global sale
competit landscap given clean safeti profil
strong efficaci relaps form ms first drug
label primari roch inject
ocrevu grow market leader quickli
launch face intensifi
competit brought ocrevu still expect biib
tecfidera maintain market share given
favor risk-benefit profil among
oral disease-modifi therapi ms
watch pdufa novn siponimod
expect top line result novn
asclepio i/ii trial ofatumumab expect
consensu forecast littl overal market growth ms compound-annual-growth-rate
global sale ocrevu
overal ms market forecast similar consensu howev
expect slower declin gilenya gener entri
conserv ramp ocrevu mainli due
strong posit tecfidera prefer oral dmt first line
ofatumumab novn mab like ocrevu
 formul instead iv infus could captur significantli
market share first-to-market ocrevu asclepio trial
demonstr better efficaci safeti data ocrevu
anticip launch gener gilenya could erod market share
brand ms drug howev launch date remain unclear rang
due on-going litig
page analyst certif import disclosur
pain market anti-ngf first answer
opioid crisi
page analyst certif import disclosur
new mechan seek answer opioid crisi call arm
current market unmet need safer effect
accord analysi chronic pain affect
pain treatment us punctuat grow
opioid crisi despit sub-optimal efficaci safeti opioid
nsaid domin pain manag account
estim global chronic pain market
agent lly/partn regn/teva effect
treatment chronic pain lower back osteoarthr
cancer pain halt due safeti issu
concert fda teva develop strategi
optim safeti cusp sever major ph trial
readout highlight develop program
upcom potenti catalyst regulatori action date nktr-
american annual cost despit high
preval pain prescript gener
consensu estim sale chronic pain
speak challeng develop novel chronic pain
therapi opportun upsid consensu estim
weigh risk/benefit late-stag chronic pain modal
consensu estim non-neuropath pain
superior efficaci
nsaid opioid
head head trial
better toler
higher risk
efficaci similar
efficaci similar
efficaci acut
pain chronic
efficaci chronic
note compani bubbl chart include- heron sorrento nektar teva regeneron therav biopharma trevena trvn acelrx pluristem
page analyst certif import disclosur
retin diseas eye benefit durat
page analyst certif import disclosur
retin diseas maxim treatment durat anti-vegf
current focu novn roch bayer/regn eylea
consensu forecast rel flat market retina diseas
eylea maintain market lead posit
share overal retina market consensu forecast
sale novn lucenti
brolucizumab abicipar pegol respect
view reflect touch consensu
lucenti rel line brolucizumab abicipar
pegol given plan year-end file brolucizumab
model vs consensu consensu model
dont yet appear includ roch ranibizumab pd
growth opportun upsid wet-amd market
product specif materi delay biosimilar lucenti
eylea biosimilar us
current market neovascular dme lead
caus vision loss us eu consensu
forecast peak global retina market sale
regn eylea forecast remain
market leader sale neovascular
dme repres retin
competit landscap eylea lead market new
agn abicipar pegol roch ranibizumab pd
focus less frequent intraocular inject
potenti disrupt market
watch brolucizumab regulatori decis
mapl namd patient
valu proposit long-act therapi clear
physician wont compromis visual acuiti safeti
expect physician see great valu longer act
treatment want compromis visual acuiti
safeti achiev eylea
specialist identifi subretin fluid number one
issu recurr namd diseas
posit novn base comparison brolucizumab
eylea retin fluid measur
roch ranibizumab pd posit phase ii
recent present gener lot excit
among physician patient go
page analyst certif import disclosur
oncolog put end great divid
page analyst certif import disclosur
oncolog one largest fastest grow therapeut area
estimate us prescript drug sale tx class gross
estimate us prescript drug sale tx class net
page analyst certif import disclosur
oncolog drug tend less vulner commerci headwind
oncolog gross price increas industri averag
estim histor price increas class
estim histor price increas class contd
overal oncolog degre generic target oncolog specif among estimate
price increas infer use iqvia sale prescript volum data
page analyst certif import disclosur
